CTL cross-reactivity among different HIV-1 clades.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

CTL cross-reactivity among different HIV-1 clades.

Conf Adv AIDS Vaccine Dev. 1997 May 4-7;:44. Unique Identifier : AIDSLINE MED/97927030
Cao H; Kanki P; Sankale JL; Kalams S; MBoup S; Walker B; Massachusetts General Hospital, Infectious Disease Unit, Boston, MA.; Fax: (617) 726-5411.

Abstract: Despite recent advances in antiviral therapy for HIV infection, successful global intervention will require an effective vaccine. Expanding evidence suggests that cytotoxic T lymphocyte (CTL) responses will be an important component of such a vaccine. The varying geographic distribution of HIV-1 clades, with the relative absence of clade B HIV-1 outside of the developed world, is considered a major obstacle to the development of a single efficacious vaccine. An understanding of cross-reactive CTL responses between different HIV-1 clades is crucial in the design of a vaccine which is broadly immunogenic. In this study, we examined whether HIV-1-specific CTL responses in African individuals infected with clade A, C or G clade viruses could recognize clade B virus. Of 14 persons evaluated, all demonstrated cross-reactivity with the US clade B viral constructs. We next evaluated the ability of HIV-1 Gag-, RT- and Env-specific CTL clones isolated from individuals infected in the US to recognize non-B viral sequences, and found that all were cross-reactive with the majority of non-B clade viral sequences. We concluded that significant CTL cross-reactivity exists between clade B and non-B clade epitopes, suggesting that a vaccine based on a single clade could induce effective cross-reactive cellular immunity.

Keywords: *HIV-1/IMMUNOLOGY *T-Lymphocytes, Cytotoxic/IMMUNOLOGY
971130
M97B1191

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .